Is Cell-Free DNA Testing in Hepatocellular Carcinoma Ready for Prime Time?

Revamping the current biomarker landscape of hepatocellular carcinoma (HCC) with cell-free DNA (cfDNA) could improve overall outcomes. The use of commercially available cfDNA testing (also known as liquid biopsy) is limited by the low prevalence of targetable mutations and does not have any prognost...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeepalyam, Sravan, Sheel, Ankur, Ejaz, Aslam, Miller, Eric, Manne, Ashish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531802/
https://www.ncbi.nlm.nih.gov/pubmed/37762533
http://dx.doi.org/10.3390/ijms241814231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531802/
https://www.ncbi.nlm.nih.gov/pubmed/37762533
http://dx.doi.org/10.3390/ijms241814231

Ejemplares similares